LYL-797

N/A

Report date: 2022/10/23 11:02:03

Base Information

Drug NameLYL-797

Drug Alias NameLYL-797

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionInactive tyrosine-protein kinase transmembrane receptor ROR1 antagonistsWnt signalling pathway modulators

TargetsInactive tyrosine-protein kinase transmembrane receptor ROR1

Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungTriple Negative Breast Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesLyell Immunopharma Inc

China Registration ClassN/A

Develop Information

Active CompaniesLyell Immunopharma Inc

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsCarcinoma, Non-Small-Cell LungTriple Negative Breast Neoplasms

Other Information

ATC CodeN/A